# TIRZEPATIDE: Clinical Guide for Practices

> Tirzepatide is a dual GLP-1/GIP receptor agonist that has demonstrated superior weight loss outcomes compared to GLP-1 monotherapy in clinical trials. Originally approved for type 2 diabetes (Mounjaro) and subsequently for weight management (Zepbound), compounded tirzepatide is in high demand for medical weight loss programs.

**FDA compounding category:** Compounding eligibility tied to FDA drug shortage status; verify current classification before prescribing  
**Category:** Weight Loss & Metabolic  
**Route of administration:** Subcutaneous injection

## Mechanism of action

Tirzepatide is a single molecule that activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, producing complementary metabolic effects [1]. GLP-1 receptor activation suppresses appetite and delays gastric emptying, while GIP receptor activation enhances insulin sensitivity and may promote fat oxidation in adipose tissue. This dual-agonist mechanism yields greater weight loss and glycemic improvement than GLP-1 receptor activation alone [3].

## Evidence summary

The SURMOUNT-1 trial demonstrated 22.5% mean body weight reduction with tirzepatide 15mg weekly at 72 weeks, significantly exceeding GLP-1 monotherapy outcomes [1]. SURMOUNT-2 confirmed efficacy in patients with type 2 diabetes, and SURMOUNT-3/4 explored sequential and maintenance therapy. FDA approved tirzepatide for type 2 diabetes (Mounjaro, May 2022) [4] and chronic weight management (Zepbound, November 2023) [2]. Head-to-head data from the SURPASS-2 trial confirmed superiority over semaglutide 1mg for glycemic control [3].

## Patient selection

Best candidates include patients with BMI of 30 or greater (or 27+ with comorbidities) who seek maximum weight loss potential, or who have plateaued on GLP-1 monotherapy [1]. Screen for the same contraindications as GLP-1 agonists: personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, history of pancreatitis, or severe GI disease [2]. Patients with both obesity and type 2 diabetes may derive particular benefit from the dual mechanism [3]. Evaluate GI tolerance history, as tirzepatide may produce more pronounced GI effects than semaglutide in some patients.

## Clinical uses

- Chronic weight management with superior efficacy to GLP-1 monotherapy
- Type 2 diabetes glycemic control
- Metabolic syndrome and insulin resistance
- Body composition optimization in obesity

## Protocols and dosing

Weekly subcutaneous injection with dose titration. Starting dose typically 2.5mg weekly, titrated every 4 weeks to target dose (up to 15mg weekly).

Standard titration per FDA labeling: 2.5mg weekly for 4 weeks, then 5mg for 4 weeks, then 7.5mg for 4 weeks, then 10mg for 4 weeks, then 12.5mg for 4 weeks, then 15mg maintenance [2]. Not all patients require maximum dose; titrate to clinical effect and tolerability. Compounded versions may require volume-based dosing adjustments. Clinical judgment should guide whether to hold at intermediate doses when adequate weight loss is achieved [1].

## Side effects to monitor

- Nausea (up to 33% at highest dose; typically transient during titration)
- Diarrhea, vomiting, constipation, and abdominal pain
- Decreased appetite (therapeutic effect but may be excessive in some patients)
- Pancreatitis (rare but serious; monitor amylase/lipase if symptomatic)
- Injection site reactions and hypersensitivity reactions (uncommon)

## Clinical considerations

Dose titration essential to minimize GI adverse effects,Same thyroid cancer contraindications as GLP-1 agonists (MTC, MEN 2),Monitor for pancreatitis and gallbladder disease,May cause more pronounced GI effects than semaglutide in some patients,Compounding eligibility tied to FDA shortage status

## Practice economics

Tirzepatide commands premium positioning within weight loss programs due to superior clinical outcomes [1], with monthly patient spend typically ranging from $400-700 for compounded formulations. Practices can differentiate by offering tirzepatide as an upgrade or second-line option for patients seeking maximum efficacy. The dual mechanism and strong trial data support premium pricing and patient willingness to pay [2].

## Frequently asked questions

### How does tirzepatide compare to semaglutide for weight loss?

Clinical trials (SURMOUNT and SURPASS programs) showed tirzepatide produced greater weight loss than semaglutide, with patients achieving 20-25% body weight reduction at maximum doses. The dual GLP-1/GIP mechanism provides additional metabolic benefits. Both are effective; tirzepatide may be preferred for patients who plateau on GLP-1 monotherapy.

### Can patients switch from semaglutide to tirzepatide?

Yes. Switching protocols are common in clinical practice. Most clinicians recommend completing semaglutide washout (1-2 weeks given the half-life), then starting tirzepatide at the lowest dose with standard titration. No direct dose equivalency exists between the two medications.

### What labs should be monitored for patients on tirzepatide?

Baseline and periodic monitoring should include A1C, fasting glucose, lipid panel, hepatic function, renal function, amylase/lipase (if pancreatitis symptoms), and thyroid function. More frequent monitoring is appropriate during dose titration.

## Sources

- [Jastreboff et al. - Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1, NEJM 2022)](https://pubmed.ncbi.nlm.nih.gov/35658024/)
- [FDA Approval of Zepbound (tirzepatide) for Chronic Weight Management](https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management)
- [Frias et al. - Tirzepatide versus Semaglutide Once Weekly (SURPASS-2, NEJM 2021)](https://pubmed.ncbi.nlm.nih.gov/34170647/)
- [FDA Approval of Mounjaro (tirzepatide) for Type 2 Diabetes](https://www.fda.gov/news-events/press-announcements/fda-approves-novel-dual-targeted-treatment-type-2-diabetes)

---

Canonical page: https://karpahealth.com/resources/peptides/tirzepatide/
Markdown version of the HTML page "tirzepatide" at that URL.
Machine-readable context: https://karpahealth.com/llms.txt · Pricing: https://karpahealth.com/pricing.md · Agents & API: https://karpahealth.com/agents.md